Indaptus Therapeutics Stock Today
| INDP Stock | USD 1.05 0.01 0.94% |
Performance0 of 100
| Odds Of DistressLess than 23
|
Indaptus Therapeutics is selling at 1.05 as of the 22nd of November 2024; that is 0.94 percent decrease since the beginning of the trading day. The stock's last reported lowest price was 1.02. Indaptus Therapeutics has about a 23 % chance of experiencing some form of financial distress in the next two years of operation but has generated negative returns over the last 90 days. Equity ratings for Indaptus Therapeutics are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 26th of May 2024 and ending today, the 22nd of November 2024. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 4th of August 2015 | Category Healthcare | Classification Health Care |
Indaptus Therapeutics, Inc., a pre-clinical biotechnology company, develops various anti-cancer and anti-viral immunotherapy products. Indaptus Therapeutics, Inc. was incorporated in 2021 and is headquartered in New York, New York. Indaptus Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. The company has 10.2 M outstanding shares of which 138.7 K shares are currently shorted by private and institutional investors with about 0.54 trading days to cover. More on Indaptus Therapeutics
Moving together with Indaptus Stock
Moving against Indaptus Stock
Follow Valuation Profit Patterns Odds of Bankruptcy
Check how we calculate scores
Indaptus Stock Highlights
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, NASDAQ Health Care, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsIndaptus Therapeutics can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Indaptus Therapeutics' financial leverage. It provides some insight into what part of Indaptus Therapeutics' total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||
Indaptus Therapeutics (INDP) is traded on NASDAQ Exchange in USA. It is located in Three Columbus Circle, New York, NY, United States, 10019 and employs 7 people. Indaptus Therapeutics is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Micro-Cap' category with a current market capitalization of 10.81 M. Indaptus Therapeutics conducts business under Biotechnology sector and is part of Health Care industry. The entity has 10.2 M outstanding shares of which 138.7 K shares are currently shorted by private and institutional investors with about 0.54 trading days to cover.
Indaptus Therapeutics currently holds about 33.01 M in cash with (13.41 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 4.0, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Check Indaptus Therapeutics Probability Of Bankruptcy
Ownership AllocationThe market capitalization of Indaptus Therapeutics is $10.81 Million. Indaptus Therapeutics secures significant amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company's outstanding shares. Note, that even with negative profits, if the true value of the firm is larger than the current market value, you may still be able to generate positive returns on investment in this company.
Check Indaptus Ownership Details
Indaptus Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Ubs Group Ag | 2024-06-30 | 692 | |
| Bangor Savings Bank | 2024-09-30 | 400 | |
| Wells Fargo & Co | 2024-06-30 | 64.0 | |
| Bank Of America Corp | 2024-06-30 | 42.0 | |
| Jpmorgan Chase & Co | 2024-06-30 | 15.0 | |
| Group One Trading, Lp | 2024-06-30 | 7.0 | |
| Qube Research & Technologies | 2024-06-30 | 1.0 | |
| Fmr Inc | 2024-09-30 | 0.0 | |
| Massmutual Trust Co Fsb/adv | 2024-09-30 | 0.0 | |
| Vanguard Group Inc | 2024-09-30 | 256.3 K | |
| Investment House Llc | 2024-09-30 | 100 K |
Indaptus Therapeutics Historical Income Statement
Indaptus Stock Against Markets
Indaptus Therapeutics Corporate Management
| MD MBA | Chief Officer | Profile | |
| Jeffrey Meckler | CEO Director | Profile | |
| Walt Esq | Chief Officer | Profile | |
| Michael Newman | Chief Founder | Profile | |
| Boyan MD | Chief Officer | Profile |
Additional Tools for Indaptus Stock Analysis
When running Indaptus Therapeutics' price analysis, check to measure Indaptus Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Indaptus Therapeutics is operating at the current time. Most of Indaptus Therapeutics' value examination focuses on studying past and present price action to predict the probability of Indaptus Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Indaptus Therapeutics' price. Additionally, you may evaluate how the addition of Indaptus Therapeutics to your portfolios can decrease your overall portfolio volatility.